X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.fiercepharma.com/pharma/ptcs-emflaza-face-generics-month-after-aurobindos-final-fda-nod
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217123
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217123
https://www.biopharmadive.com/news/sarepta-surprise-fda-rejection-duchenne-vyondys-53/561200/
http://www.pharmatimes.com/news/sareptas_dmd_drug_hit_with_fda_complete_response_letter_1298245
https://www.biopharmadive.com/news/sarepta-gene-therapy-duchenne-vyondys-53-setback/561285/
https://www.fiercebiotech.com/biotech/fda-surprises-sarepta-by-spurning-its-second-duchenne-drug
https://endpts.com/icer-blasts-fda-ptc-and-sarepta-for-high-prices-on-dmd-drugs-emflaza-exondys-51/?utm_medium=email&utm_campaign=790%20Friday%20August%2016%20-%206%20years%20after%20Sanofi%20killed%20it%20fedratinib%20wins%20FDA%20OK%20Top%2010%20franchise%20drugs%20in%20history%20offer%2014T%20lesson&utm_content=790%20Friday%20August%2016%20-%206%20years%20after%20Sanofi%20killed%20it%20fedratinib%20wins%20FDA%20OK%20Top%2010%20franchise%20drugs%20in%20history%20offer%2014T%20lesson+CID_0faf5d59b692c300e4ef716e0fddccee&utm_source=ENDPOINTS%20emails&utm_term=ICER%20blasts%20FDA%20PTC%20and%20Sarepta%20for%20high%20prices%20on%20DMD%20drugs%20Emflaza%20Exondys%2051
https://www.prnewswire.com/news-releases/ptc-therapeutics-receives-fda-approval-for-the-expansion-of-the-emflaza-deflazacort-labeling-to-include-patients-2-5-years-of-age-300863988.html
https://www.biopharmadive.com/news/could-novartis-gene-therapy-have-more-than-one-price/555453/
https://www.fiercebiotech.com/biotech/idorsia-sheds-surplus-dmd-therapy-to-santhera
http://www.pmlive.com/pharma_news/mallinckrodt_doses_first_patient_in_muscular_dystrophy_trial_1246911
https://www.fiercepharma.com/financials/ptc-hot-seat-again-over-price-hikes-dmd-med-emflaza
https://endpts.com/the-next-emflaza-acer-therapeutics-looks-to-take-a-page-out-of-marathons-book/
https://www.biospace.com/article/exclusive-ptc-therapeutics-ceo-to-fight-for-dmd-therapy-pushes-forward-with-sma-treatment/
https://www.fiercebiotech.com/biotech/after-disappointing-2016-new-drug-approvals-roared-back-to-life-2017
http://www.cnbc.com/2017/05/08/new-price-for-muscular-dystrophy-drug-draws-criticism.html
http://www.fiercepharma.com/pharma/ptc-therapeutics-set-for-emflaza-launch-35-000-price-tag
http://www.biospace.com/News/embattled-marathon-pharma-may-shutter-operations/453593/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
https://hbr.org/2017/04/the-cost-of-drugs-for-rare-diseases-is-threatening-the-u-s-health-care-system
http://www.huffingtonpost.com/entry/sky-high-drug-prices-for-rare-diseases-show-why-orphan_us_58cd353de4b07112b6472ded
http://www.fiercepharma.com/pharma/marathon-under-heavy-fire-for-emflaza-pricing-makes-surprise-deal-to-sell-drug-for-140m-plus
http://www.fiercepharma.com/pharma/eight-senators-pile-to-marathon-s-emflaza-pricing-blunder
http://raps.org/Regulatory-Focus/News/2017/03/06/27032/Senators-Ask-GAO-to-Probe-Orphan-Drug-Act-as-Questions-Pile-up-Over-Marathon%E2%80%99s-Pricey-Steroid/
http://www.biospace.com/News/crispr-cas9-startup-exonics-therapeutics-launches/447825/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.biospace.com/News/first-ariad-now-senator-bernie-sanders-puts-this/446873/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
https://medicalxpress.com/news/2017-02-lawmakers-pricing-drug-genetic-disease.html
http://www.forbes.com/sites/matthewherper/2017/02/10/a-6000-price-hike-should-give-drug-companies-a-disgusting-sense-of-deja-vu/#204fae157327
https://endpts.com/another-biotech-games-the-system-and-everyone-gets-to-pay-for-the-fallout/
http://www.fiercepharma.com/pharma/details-short-as-biopharma-execs-talk-potential-changes-to-u-s-environment
http://www.prnewswire.com/news-releases/fda-approves-drug-to-treat-duchenne-muscular-dystrophy-300405176.html
http://www.fiercebiotech.com/biotech/marathon-hopes-to-succeed-where-others-have-fallen-duchenne-nda
http://www.pharma-excipients.ch/2016/05/19/formulation-and-evaluation-of-deflazacort-liquisolid-tablets/
http://www.prnewswire.com/news-releases/marathon-pharmaceuticals-announces-nationwide-expanded-access-program-for-patients-with-duchenne-muscular-dystrophy-dmd-300233075.html
Market Place
Share 
